65,437 trials
Acute Lymphoblastic Leukemia · Adult B Lymphoblastic Lymphoma · Ann Arbor Stage I B Lymphoblastic Lymphoma
Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability
Atherosclerosis, Coronary
Primary: Comparison of CT Based FFR With Invasive FFR, ROC Analysis — 0.8 probability of accurate diagnosis
Castleman Disease · Multicentric Castleman Disease · Giant Lymph Node Hyperplasia
Primary: Percentage of Participants With an Overall Clinical Benefit Response — 63; 100; 50; 67 percentage of participants
Breast Cancer
Primary: Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients. — 91; 90…
Adenosquamous Lung Carcinoma · Bronchioloalveolar Carcinoma · Large Cell Lung Carcinoma
Primary: Percentage of Participants Alive Without Progression (Progression-free Survival) — 60.4; 51.3 percentage of participants — p=0.7563
Breastfeeding · Intention · Health Behavior
Primary: Number of Participants Who Intended to Exclusively Breastfeed Post-intervention — 40; 36; 86; 67 Participants
Crohn's Disease
Primary: Percentage of Participants Achieving Clinical Remission at Week 52 — 34.3; 48.0 percentage of participants — p=0.008
Visual Acuity
Primary: CLUE Vision — 52.77; 52.23 units on a scale
Chronic Gout · Hyperuricemia
Primary: Oxypurinol Renal Clearance — 1.9; 1.4; 1.6 L/hr
Post Traumatic Stress Disorder
Primary: The Trauma History Questionnaire (THQ; Green, 1996) — 5.93; 0.76; 3.81; 0.97 score on a scale
Obsessive-Compulsive Disorder
Primary: Yale-Brown Obsessive-Compulsive Challenge Scale (YBOC-CS) — 17.45; 17.00; 17.09; 13.36 score on a scale — p=.577
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Mantle Cell Lymphoma
Primary: Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) During Phase I — 0; 0; 0; 0 Participants
Hypereosinophilic Syndrome
Primary: Number of Participants With Common (>=3%) Non-serious Adverse Events (AEs) — 34 Participants
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Primary: Change From Baseline in ATPmax (Maximal ATP Synthetic Rate) — 0.17; 0.12; 0.09; 0.06 mM/sec
Stage I Mantle Cell Lymphoma · Stage II Contiguous Mantle Cell Lymphoma · Stage II Non-Contiguous Mantle Cell Lymphoma
Primary: Proportion of Patients Experiencing a Complete Response — .62 Proportion of participants